Results from Phase 1 Trial of VT3989, a First-in-Class TEAD Autopalmitoylation Inhibitor, to be Reported in an Oral Presentation at AACR Annual Meeting 2023 SAN MATEO, Calif., March 15, 2023 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.